Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Marina O. Popova"'
Autor:
Mikhail S. Nozhkin, Dmitry A. Lioznov, Tamara V. Antonova, Olga V. Gorchakova, Edward M. Goldstein, Marina O. Popova, Tatyana V. Shneyder
Publikováno v:
Терапевтический архив, Vol 95, Iss 11, Pp 919-923 (2023)
The study evaluated the impact of HCV infection on the prognosis in patients with hematological malignancies. A total of 96 patients with anti-HCV antibodies were enrolled, with the age of 37.8 (3.0–81.0) years old, 39.6% had non-Hodgkin’s lympho
Externí odkaz:
https://doaj.org/article/598f4e690e3e4ea090844d13ac417b2e
Autor:
Kirill V. Lepik, Liudmila V. Fedorova, Elena V. Kondakova, Yuri R. Zalyalov, Elena V. Babenko, Elena E. Lepik, Polina V. Kotselyabina, Anastasia V. Beynarovich, Marina O. Popova, Nikita P. Volkov, Lilia V. Stelmakh, Vadim V. Baykov, Ivan S. Moiseev, Natalia B. Mikhailova, Alexander D. Kulagin, Boris V. Afanasyev
Publikováno v:
HemaSphere, Vol 4, Iss 5, p e480 (2020)
Abstract. The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldw
Externí odkaz:
https://doaj.org/article/26c4ae48c6e54f8491d5fcf760d55f6c
Autor:
Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Liudmila V. Fedorova, Luibov A. Tsvetkova, Polina V. Kotselyabina, Evgeniya S. Borzenkova, Elena V. Babenko, Marina O. Popova, Elena I. Darskaya, Vadim V. Baykov, Ivan S. Moiseev, Boris V. Afanasyev
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e401 (2020)
Abstract. This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received
Externí odkaz:
https://doaj.org/article/4007f47d8ed2482b85babff63061e790
Autor:
Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Kamil D. Kaplanov, Andrei A. Petrenko, Oksana I. Ochirova, Alina Karpova, Ekaterina Yu. Chelysheva, Anna G. Turkina, Margarita A. Gurianova, Liubov S. Al-Radi, Elena A. Gilyazitdinova, Elena K. Egorova, Yulia A. Chabaeva, Sergey M. Kulikov, Yulia V. Sveshnikova, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika F. Rakhmani, Olga L. Panteleeva, Maria E. Grishunina, Olga S. Samoylova, Ekaterina Vorontsova, Daria V. Baryshnikova, Elena N. Parovichnikova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeed11ea33a0b517984c8fbcb6a2dfc0
https://doi.org/10.1016/j.clml.2023.04.002
https://doi.org/10.1016/j.clml.2023.04.002
Autor:
Aleksandr A. Siniaev, A.O. Grinenko, Marina O. Popova, Yu.A. Rogacheva, A.A. Spiridonova, Yu.Yu. Vlasova, A.G. Smirnova, E.V. Morozova, K.V. Lepik, N.B. Mikhailova, M.D. Vladovskaya, S.N. Bondarenko, I.S. Moiseev, A.D. Kulagin
Publikováno v:
Clinical Microbiology and Antimicrobial Chemotherapy. 24:196-201
Objective. To assess the course and outcomes of COVID-19 in recipients of allogeneic and autologous hematopoietic stem cell transplant (HSCT). Materials and Methods. The retrospective study included 44 adult recipients (allogeneic – 33 [75%] and au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d4605820e7e0368099123466ca5d7d
https://doi.org/10.36488/cmac.2022.3.196-201
https://doi.org/10.36488/cmac.2022.3.196-201
Autor:
Yu.A. Rogacheva, Marina O. Popova, Aleksandr A. Siniaev, A.A. Spiridonova, V.V. Markelov, Yu.Yu. Vlasova, S.N. Bondarenko, L.S. Zubarovskaya, A.D. Kulagin
Publikováno v:
Clinical Microbiology and Antimicrobial Chemotherapy. 24:375-382
Objective. To study epidemiology and impact of colonization by multidrug-resistant Gram-negative bacteria (MDRGNB) on bloodstream infections (BSI) during allogeneic hematopoietic stem cell transplantation (allo-HSCT). Materials and Methods. The retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20f9c2f12fe0cc9650e3430d760132d5
https://doi.org/10.36488/cmac.2022.4.375-382
https://doi.org/10.36488/cmac.2022.4.375-382
Autor:
Yu.V. Dinikina, E.V. Shagdileeva, Sofya N. Khostelidi, O.V. Shadrivova, Yu.L. Avdeenko, A.G. Volkova, Marina O. Popova, L.S. Zubarovskaya, T.S. Bogomolova, S.M. Ignatyeva, Alexey S. Kolbin, M.B. Belogurova, E.G. Boychenko, Nikolay N. Klimko
Publikováno v:
Clinical Microbiology and Antimicrobial Chemotherapy. :14-22
Objective. To study risk factors, etiology, clinical signs and treatment outcomes of invasive aspergillosis (IA) and mucormycosis combination (IAM) in children. Materials and Methods. A retrospective review of Saint-Petersburg register (1998–2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f8c04b4ea8d59726fea86fb21b8dbf
https://doi.org/10.36488/cmac.2022.1.14-22
https://doi.org/10.36488/cmac.2022.1.14-22
Autor:
Marina O. Popova, Yu.A. Rogacheva
Publikováno v:
Клиническая микробиология и антимикробная химиотерапия, Vol 23, Iss 3, Pp 226-238 (2021)
Over the last decade, the introduction of new antifungal drugs and diagnostic procedures has improved the prognosis of hematological patients with invasive fungal disease (IFD), primarily invasive aspergillosis. Despite effective antifungal prophylax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87f5cf4f835c48e42275ba6a06a40e68
https://cmac-journal.ru/publication/2021/3/cmac-2021-t23-n3-p226/cmac-2021-t23-n3-p226.pdf
https://cmac-journal.ru/publication/2021/3/cmac-2021-t23-n3-p226/cmac-2021-t23-n3-p226.pdf
Autor:
Irina B. Baranova, A.I. Yaremenko, A.A. Zubareva, S.A. Karpischenko, Marina O. Popova, A.A. Kurus, G.V. Portnov, O.N. Pinegina, O.V. Lukina, M.V. Malyarevskaya, I.N. Kalakuckiy, M.O. Ilyukhina, Nikolay N. Klimko
Publikováno v:
Clinical Microbiology and Antimicrobial Chemotherapy. 23:347-358
Currently, the relevance of the issues of diagnosis and treatment of invasive fungal diseases has increased significantly due to the pandemic of a new coronavirus infection COVID-19 and the massive use of corticosteroids for the treatment. The key su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89b5a875a8be2ca47f31b7c78659532b
https://doi.org/10.36488/cmac.2021.4.347-358
https://doi.org/10.36488/cmac.2021.4.347-358
Autor:
Sergey Dubov, Valery G. Savchenko, Lev S. Butaev, Hunan Julhakyan, Yulia Sveshnikova, Inessa Yu. Toropova, Oksana Ochirova, Olga A. Gavrilina, E A Gilyazitdinova, Aleksandr A. Siniaev, Vasily Shuvaev, Anastasia N. Vasileva, Lubov Gavrilova, Maria Grishunina, Kristina Zakurdaeva, Mikhail A. Kunst, Marina O. Popova, Vladimir I. Vorobyev, K D Kaplanov, Al'-Radi Ls, Andrei Petrenko, Yulia A. Chabaeva, Daria Baryshnikova, Vitaly S. Dubov
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background Patients (pts) with lymphoproliferative diseases (LPD) are at high risk of COVID-19 severe and lethal course. Objective To evaluate treatment outcomes and risk factors in pts with LPD and COVID-19 in a real-world setting. Methods CHRONOS19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac386586f20ac7457204c2d72791da1
http://europepmc.org/articles/PMC8404062
http://europepmc.org/articles/PMC8404062